Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

Role of Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in the Pathophysiology of Ischemic Stroke in Human and Albino Rats

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05748587

Enrollment

Registered

2023-02-28

Start date

2023-04-01

Completion date

2024-04-01

Last updated

2024-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Ischemia

Brief summary

This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are: * Is there an association between iron and alpha-synuclein accumulation in ischemic stroke? * Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?

Interventions

DIAGNOSTIC_TESTBrain lymphocyte activation gene

LAG-3 expression in rat's brain

DRUGDeferoxamine

intramuscular deferoxamine (200 mg/kg) injection to rats

DIAGNOSTIC_TESTSerum Iron

Serum iron levels in study groups

DIAGNOSTIC_TESTRBCs Alpha-synuclein

α-syn levels in RBCs

DIAGNOSTIC_TESTSerum Soluble lymphocyte activation gene

sLAG-3 in the serum of study groups

RADIATIONBrain computed tomography

Brain CT of patients after admission

DIAGNOSTIC_TESTBrain Iron

Iron in brain homogenate of rats

DIAGNOSTIC_TESTBrain Alpha-synuclein

α-syn expression in rat's brain

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

50 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Patients at the age between 50-70 years. 2. Patients having neurological symptoms of acute ischemic stroke.

Exclusion criteria

1. Patients with acute hemorrhagic stroke. 2. Patients with Parkinson's disease (PD). 3. Patients with dementia, and Alzheimer's disease. 4. Patients with any type of malignancy. 5. Patients with central nervous system infection.

Design outcomes

Primary

Measure	Time frame	Description
Iron levels	6 months	Serum iron levels in ischemic patients and control
Alpha-synuclein levels	6 months	Alpha-synuclein levels in RBCs in ischemic patients and control
Levels of Soluble lymphocyte activation gene-3	6 months	Serum soluble lymphocyte activation gene-3 in ischemic patients and control
levels of iron, alpha-synuclein, and soluble lymphocyte activation in relation to stroke severity and infarction size	6 months	stroke severity will be evaluated by the National Institutes of Health Stroke Scale (NIHSS) and size of infarction will be detected by brain CT
Iron levels in brain of rats	2 months	Iron levels in brain homogenate of rats in the three rat groups
Levels of Alpha-synuclein expression in brain of rats	2 months	Alpha-synuclein expression in brain of rats in different groups
Levels of Lymphocyte activation gene-3 expression in brain of rats	2 months	lymphocyte activation gene-3 expression in brain of rats in different groups

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026